Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | HINT1 | P49773 | 3/20 | 0.40 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.39 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.39 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.39 |
| ▸ | POLA1 | P09884 | 1/20 | 0.38 |
| ▸ | STING1 | Q86WV6 | 4/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.37 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16987234 | 0.87 | KDM4E (0.51) | KDM4EPOLBHPGDF2HINT1 | |
| SCHEMBL17597174 | 0.85 | POLB (0.55) | KDM4EPOLBF2HINT1P2RY2 | |
| SCHEMBL3292642 | 0.85 | DNMT1 (0.51) | KDM4EPOLBPDE3A | |
| SCHEMBL30591564 | 0.85 | HINT1 (0.49) | HPGDHINT1FUT5 | |
| SCHEMBL15302164 | 0.84 | TYMP (0.46) | KDM4EPOLBHPGDF2HINT1 | |
| SCHEMBL3278946 | 0.80 | KDM4E (0.48) | KDM4EPOLBHPGDF2HINT1 | |
| SCHEMBL3279868 | 0.79 | POLB (0.56) | KDM4EPOLBHPGDF2HINT1 | |
| SCHEMBL16359975 | 0.79 | POLB (0.56) | KDM4EPOLBHPGDF2HINT1 | |
| SCHEMBL3279870 | 0.79 | POLB (0.56) | KDM4EPOLBHPGDF2HINT1 | |
| SCHEMBL1919146 | 0.79 | HINT1 (0.58) | HINT1FUT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220000900-A1 | Oligonucleotide Analogues Incorporating 5-Aza-Cytosine Therein | ASTEX PHARMACEUTICALS INC (US) | 2022-01-06 | — | — | US | disclosed |
| US-10933079-B2 | Oligonucleotide analogues incorporating 5-aza-cytosine therein | ASTEX PHARMACEUTICALS, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-20200215092-A1 | Oligonucleotide Analogues Incorporating 5-Aza-Cytosine Therein | ASTEX PHARMACEUTICALS, INC. | 2020-07-09 | — | — | US | disclosed |
| US-10456415-B2 | Oligonucleotide analogues incorporating 5-aza-cytosine therein | ASTEX PHARMACEUTICALS, INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-20170035794-A1 | Oligonucleotide Analogues Incorporating 5-Aza-Cytosine Therein | ASTEX PHARMACEUTICALS, INC. | 2017-02-09 | — | — | US | disclosed |
| US-9480698-B2 | Oligonucleotide analogues incorporating 5-aza-cytosine therein | ASTEX PHARMACEUTICALS, INC. (US) | 2016-11-01 | — | — | US | disclosed |
| US-9358248-B2 | Oligonucleotide analogues incorporating 5-aza-cytosine therein | ASTEX PHARMACEUTICALS, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-20160130296-A1 | Oligonucleotide Analogues Incorporating 5-Aza-Cytosine Therein | ASTEX PHARMACEUTICALS, INC. | 2016-05-12 | — | — | US | disclosed |
| EP-2944646-A1 | Oligonucleotide analogues incorporating 5-aza-cytosine therein | Astex Pharmaceuticals, Inc. (US) | 2015-11-18 | — | — | EP | disclosed |
| EP-1943264-B1 | OLIGONUCLEOTIDE ANALOGUES INCORPORATING 5-AZA-CYTOSINE THEREIN | ASTEX PHARMACEUTICALS INC (US) | 2015-07-29 | — | — | EP | disclosed |
| US-20130236536-A1 | Oligonucleotide Analogues Incorporating 5-Aza-Cytosine Therein | ASTEX PHARMACEUTICALS, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| US-8461123-B2 | Oligonucleotide analogues incorporating 5-aza-cytosine therein | ASTEX PHARMACEUTICALS, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20100215729-A1 | OLIGONUCLEOTIDE ANALOGUES INCORPORATING 5-AZA-CYTOSINE THEREIN | SUPERGEN, INC. | 2010-08-26 | — | — | US | disclosed |
| US-7700567-B2 | methylation modulators; phosphoramidite building blocks; for treating cancer and hematological disorders | SUPERGEN, INC. (US) | 2010-04-20 | — | — | US | disclosed |
| US-20070072796-A1 | methylation modulators; phosphoramidite building blocks; for treating cancer and hematological disorders | ASTEX PHARMACEUTICALS, INC. | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200215092-A1 | Oligonucleotide Analogues Incorporating 5-Aza-Cytosine Therein | DCTD, DNMT3B, NT5C3B | KDM4E 1041/4885POLB 52/4885HPGD 1248/4885 |
| US-20220000900-A1 | Oligonucleotide Analogues Incorporating 5-Aza-Cytosine Therein | DCTD, DNMT3B, NT5C3B | KDM4E 1041/4885POLB 52/4885HPGD 1248/4885 |
| US-20130236536-A1 | Oligonucleotide Analogues Incorporating 5-Aza-Cytosine Therein | DCTD, DNMT3B, NT5C3B | KDM4E 1041/4885POLB 52/4885HPGD 1248/4885 |
| US-10456415-B2 | Oligonucleotide analogues incorporating 5-aza-cytosine therein | DCTD, DNMT3B, NT5C3B | KDM4E 1041/4885POLB 52/4885HPGD 1248/4885 |
| US-20160130296-A1 | Oligonucleotide Analogues Incorporating 5-Aza-Cytosine Therein | DCTD, DNMT3B, NT5C3B | KDM4E 1041/4885POLB 52/4885HPGD 1248/4885 |
| US-10933079-B2 | Oligonucleotide analogues incorporating 5-aza-cytosine therein | DCTD, DNMT3B, NT5C3B | KDM4E 1041/4885POLB 52/4885HPGD 1248/4885 |
| US-20170035794-A1 | Oligonucleotide Analogues Incorporating 5-Aza-Cytosine Therein | DCTD, DNMT3B, NT5C3B | KDM4E 1041/4885POLB 52/4885HPGD 1248/4885 |
| US-20100215729-A1 | OLIGONUCLEOTIDE ANALOGUES INCORPORATING 5-AZA-CYTOSINE THEREIN | DCTD, DNMT3B, NT5C3B | KDM4E 1041/4885POLB 52/4885HPGD 1248/4885 |
| US-20070072796-A1 | methylation modulators; phosphoramidite building blocks; for treating cancer and hematological disorders | DCTD, DNMT3B, NT5C3B | KDM4E 647/4885POLB 37/4885HPGD 1087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.